The Radiobiology and Imaging Program has been continuously approved by the NCI Cancer Center Support Grant since 1987. The Program seeks to improve patient outcomes through the advanced understanding of how ionizing and non-ionizing radiation interacts with cancer and normal tissues. The Programmatic goals are to: (1) Study molecular mechanisms of radiation response and identify targets to improve radiotherapy. (2) Elucidate mechanisms underlying use of Photodynamic Therapy (PDT) and translate to the clinic. (3) Develop methods for measuring and altering tumor oxygenation and metabolic status; understand the molecular events governing cell death by IR and physiological stresses. (4) Develop novel techniques to image the interaction between radiation, PDT and tissues. (5) Understand the biological effects of protons to inform their effective clinical use. The Program was rated as ?Exceptional? at the time of the 2010 CCSG renewal application and is led by Constantinos Koumenis, PhD, Professor and Director of the Research Division of Radiation Oncology and Amit Maity, MD, PhD, Professor of Radiation Oncology. Drs. Maity and Koumenis are NCI-funded researchers who bring their scientific vision to this Program, which is focused on basic and translational research and the development of investigator-initiated trials. Since the last renewal, the Co- Leaders have recruited new junior and senior scientists, enhanced collaborative peer-reviewed funding and increased the number of investigator-initiated clinical trials involving radiotherapy and imaging. Moreover, Drs. Koumenis and Maity have steered the Program towards new areas of emphasis including combined radiation and immunotherapy modalities and precision medicine and they have expanded the incorporation of imaging modalities into basic and translational efforts. Through this process, they increased interactions with the Immunobiology, Cancer Therapeutics, Breast Cancer and Cancer Control Programs. A major development has been the substantial expansion of both translational and clinical studies of proton therapy. Program members represent six departments from four schools at Penn. During the past five years, translational research has continued to be a major focus. The 33 Program members have $7.7M in research grant funding (annual direct costs), of which $7.5M is peer-reviewed and $3.7M is NCI-funded. There were a total of 405 cancer-related publications authored by Program members during the project period. Of these, 19% are intra- Programmatic, 28% are inter-Programmatic and 53% are multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-43
Application #
9618149
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542

Showing the most recent 10 out of 1047 publications